Topical application of the antiapoptotic TAT-FNK protein prevents aminoglycoside-induced ototoxicity

Gene Ther. 2012 Dec;19(12):1141-9. doi: 10.1038/gt.2011.204. Epub 2011 Dec 22.

Abstract

We previously demonstrated that an artificial protein, TAT-FNK, has antiapoptotic effects against cochlear hair cell (HC) damage caused by ototoxic agents when applied systemically. To examine the feasibility of topical protein therapy for inner ear disorders, we investigated whether gelatin sponge soaked with TAT-FNK and placed on the guinea pig round window membrane (RWM) could deliver the protein to the cochlea and attenuate aminoglycoside (AG)-induced cochlear damage in vivo. First, we found that the immunoreactivity of TAT-myc-FNK was distributed throughout the cochlea. The immunoreactivity was observed from 1-24 h after application. When Tat-FNK was applied 1 h before ototoxic insult (a combination of kanamycin sulfate and ethacrynic acid), auditory brainstem response threshold shifts and the extent of HC death were significantly attenuated. When cochlear organotypic cultures prepared from P5 rats were treated with kanamycin, TAT-FNK significantly reduced the extent of caspase-9 activation and HC death. These findings indicate that TAT-FNK topically applied on the RWM can enter the cochlea by diffusion and effectively prevent AG-induced apoptosis of cochlear HCs by suppressing the mitochondrial caspase-9 pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Aminoglycosides / toxicity*
  • Animals
  • Apoptosis / drug effects*
  • Caspase 9 / metabolism
  • Cochlea / drug effects*
  • Cochlea / metabolism
  • Ethacrynic Acid / pharmacology
  • Ethacrynic Acid / toxicity
  • Evoked Potentials, Auditory, Brain Stem / drug effects
  • Gene Products, tat / administration & dosage
  • Gene Products, tat / pharmacology*
  • Guinea Pigs
  • Hair Cells, Auditory / drug effects
  • Kanamycin / pharmacology
  • Labyrinth Diseases / chemically induced
  • Labyrinth Diseases / prevention & control*
  • Neuroprotective Agents
  • Protein Serine-Threonine Kinases / administration & dosage
  • Protein Serine-Threonine Kinases / pharmacology*
  • Rats
  • Recombinant Fusion Proteins / administration & dosage*
  • Recombinant Fusion Proteins / pharmacology
  • Round Window, Ear
  • Tumor Suppressor Proteins

Substances

  • Aminoglycosides
  • Gene Products, tat
  • Neuroprotective Agents
  • Recombinant Fusion Proteins
  • TAT-FNK fusion protein
  • Tumor Suppressor Proteins
  • Kanamycin
  • PLK3 protein, human
  • Protein Serine-Threonine Kinases
  • Caspase 9
  • Ethacrynic Acid